IRIS
GERRATANA, Lorenzo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.971
AS - Asia 4.100
EU - Europa 2.367
SA - Sud America 592
Continente sconosciuto - Info sul continente non disponibili 539
AF - Africa 96
OC - Oceania 3
Totale 16.668
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.656
SG - Singapore 1.865
CN - Cina 763
IT - Italia 718
BR - Brasile 463
HK - Hong Kong 385
DE - Germania 374
VN - Vietnam 349
BD - Bangladesh 227
RU - Federazione Russa 216
UA - Ucraina 181
FR - Francia 174
IN - India 162
GB - Regno Unito 141
CA - Canada 136
FI - Finlandia 88
IE - Irlanda 85
SE - Svezia 72
TR - Turchia 54
NL - Olanda 46
KR - Corea 45
AR - Argentina 42
JP - Giappone 42
PL - Polonia 41
AT - Austria 37
BE - Belgio 36
MX - Messico 35
ES - Italia 32
CZ - Repubblica Ceca 31
ZA - Sudafrica 31
IQ - Iraq 30
CO - Colombia 25
ID - Indonesia 19
LT - Lituania 19
CR - Costa Rica 18
EC - Ecuador 18
IL - Israele 17
PK - Pakistan 17
CH - Svizzera 16
NI - Nicaragua 16
RO - Romania 16
JM - Giamaica 15
VE - Venezuela 15
GP - Guadalupe 14
HN - Honduras 14
SA - Arabia Saudita 14
TT - Trinidad e Tobago 14
GT - Guatemala 12
IR - Iran 12
CW - ???statistics.table.value.countryCode.CW??? 11
EG - Egitto 11
UZ - Uzbekistan 10
AE - Emirati Arabi Uniti 9
AZ - Azerbaigian 8
CL - Cile 8
MA - Marocco 8
PR - Porto Rico 8
PY - Paraguay 8
SC - Seychelles 8
SV - El Salvador 8
DZ - Algeria 7
EE - Estonia 7
NP - Nepal 7
TH - Thailandia 7
BO - Bolivia 6
PH - Filippine 6
TN - Tunisia 6
DK - Danimarca 5
KZ - Kazakistan 5
LB - Libano 5
LV - Lettonia 5
MY - Malesia 5
BB - Barbados 4
BS - Bahamas 4
JO - Giordania 4
KE - Kenya 4
LA - Repubblica Popolare Democratica del Laos 4
NO - Norvegia 4
OM - Oman 4
PA - Panama 4
RS - Serbia 4
SN - Senegal 4
SY - Repubblica araba siriana 4
TG - Togo 4
UY - Uruguay 4
AL - Albania 3
AM - Armenia 3
BZ - Belize 3
EU - Europa 3
GR - Grecia 3
HU - Ungheria 3
MF - Saint Martin 3
PE - Perù 3
AU - Australia 2
BG - Bulgaria 2
BY - Bielorussia 2
CI - Costa d'Avorio 2
DO - Repubblica Dominicana 2
ET - Etiopia 2
GE - Georgia 2
Totale 16.106
Salva come PNG Salva come JPEG
Città #
Ashburn 1.064
Singapore 874
Fairfield 717
San Jose 644
Council Bluffs 453
Chandler 446
Hong Kong 381
Woodbridge 347
Beijing 327
Seattle 307
Houston 287
Wilmington 244
Cambridge 227
Ann Arbor 207
Boardman 190
Los Angeles 177
Frankfurt am Main 160
New York 158
Lauterbourg 126
Santa Clara 118
Dearborn 115
Dallas 104
Jacksonville 100
Ho Chi Minh City 98
Buffalo 80
Dublin 79
Princeton 77
Munich 69
Hanoi 66
Dong Ket 64
Milan 62
The Dalles 59
Phoenix 58
Udine 54
Chicago 52
Hefei 50
Rome 50
São Paulo 50
Denver 43
Redondo Beach 42
Seoul 42
Montreal 41
San Diego 41
Tokyo 40
Washington 40
North Bergen 39
Orem 38
Warsaw 38
Brooklyn 34
Toronto 34
Helsinki 32
Stockholm 30
Atlanta 29
Brussels 29
Naples 29
Izmir 27
London 26
Martignacco 26
Ogden 26
Redmond 26
Brno 25
Des Moines 25
Chennai 24
Nuremberg 23
Turku 22
Charlotte 21
Johannesburg 21
Trieste 19
Belluno 18
Vienna 18
Boston 17
Shanghai 17
Guangzhou 16
Mexico City 16
Poplar 16
Amsterdam 15
Da Nang 15
Manchester 15
San Francisco 15
Zurich 15
Managua 14
Mumbai 14
Hyderabad 13
Lappeenranta 13
Newark 13
Ankara 12
Baghdad 12
Falls Church 12
Nanjing 12
Norwalk 12
Philadelphia 12
San José 12
Düsseldorf 11
Belo Horizonte 10
Brasília 10
Chaguanas 10
Changsha 10
City of London 10
Guatemala City 10
Jinan 10
Totale 10.098
Salva come PNG Salva come JPEG
Nome #
In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis 239
The SLICE study: The prognostic role of visceral fat in metastatic colorectal cancer 232
Luminal-like HER2-negative stage IA breast cancer: A multicenter retrospective study on long-term outcome with propensity score analysis 206
Lactate Dehydrogenase (LDH) Response to First-Line Treatment Predicts Survival in Metastatic Breast Cancer: First Clues for A Cost-Effective and Dynamic Biomarker 204
Pattern of metastasis and outcome in patients with breast cancer 203
First steps in the definition of a prognostic score based on MGMT methylation status in patients with glioblastoma 201
MGMT pyrosequencing-based cut-off methylation level and clinical outcome in patients with glioblastoma multiforme 198
Mucosal Injury during Anti-Cancer Treatment: From Pathobiology to Bedside 198
Comparison of primary breast cancer and paired metastases: biomarkers discordance influence on outcome and therapy 197
Neutrophil-to-lymphocyte and lymphocyte-to-monocyte ratios in breast cancer 195
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype 194
Androgen receptor in estrogen receptor positive breast cancer: Beyond expression 192
Longitudinal profiling of hormone receptor positive, HER2 negative metastatic breast cancer through droplet digital PCR-based circulating tumor DNA fragmentomics 184
Measures of outcome in metastatic breast cancer: insights from a real-world scenario. 184
Defining a prognostic score based on O6-methylguanine-DNA methyltransferase cut-off methylation level determined by pyrosequencing in patients with glioblastoma multiforme 181
Emerging Role of Genomics and Cell-Free DNA in Breast Cancer 176
Third-generation tyrosine kinase inhibitor in the treatment of epidermal growth factor receptor mutated squamous cell lung cancer: a tailored therapy approach 175
Real-time tests of multiple genome alterations take the first steps into the clinic: a learning example 174
Caring for cancer survivors: perspectives of oncologists, general practitioners and patients in Italy 171
Prognostic role of disease extent and lymphocyte-monocyte ratio in advanced melanoma 171
Treatment of metastatic breast cancer in a real-world scenario: Is progression-free survival with first line predictive of benefit from second and later lines? 169
APE1 and NPM1 protect cancer cells from platinum compounds cytotoxicity and their expression pattern has a prognostic value in TNBC 168
A risk score integrating lymphocytes ratios (LRs) and lactate dehydrogenase (LDH) levels to predict prognosis in metastatic breast cancer (MBC) patients 165
International expert consensus on the clinical integration of circulating tumor cells in solid tumors 164
Prognostic role of disease extent and lymphocyte-monocyte ratio in advanced melanoma 164
1781P Feasibility of an automated data solution for Binary Alignment Map (BAM) files generated through next generation sequencing (NGS) of circulating tumor DNA (ctDNA) 163
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study 162
Do platinum salts fit all triple negative breast cancers? 162
The role of sidedness in second-line therapy for RAS wild-type colorectal cancer: a network meta-analysis (NMA) 160
Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time? 158
Monocyte-to-lymphocyte ratio in metastatic colorectal cancer: Prognostic role evaluation and cut-off definition 155
Tumour-infiltrating lymphocytes, programmed death ligand 1 and cyclooxygenase-2 expression in skin melanoma of elderly patients: clinicopathological correlations. 150
Controversies in monitoring metastatic breast cancer during systemic treatment. Results of a GIM (Gruppo Italiano Mammella) survey 148
Role of Bruton's Tyrosine Kinase in Stage III Colorectal Cancer 147
Selecting patients for gastrectomy in metastatic esophago-gastric cancer: Clinics and pathology are not enough 147
Monitoring metastatic breast cancer (M-MBC) during treatment: a GIM (Gruppo Italiano Mammella) survey 147
Biologically driven cut-off definition of lymphocyte ratios in metastatic breast cancer and association with exosomal subpopulations and prognosis 147
Small luminal-like breast cancer: determinants of adjuvant chemotherapy use 146
Plasma-Based Longitudinal Evaluation of ESR1 Epigenetic Status in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer 145
Clinical impact of body mass index on palbociclib treatment outcomes and effect on exposure 144
The IMPACT study: early loss of skeletal muscle mass in advanced pancreatic cancer patients 143
KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC 142
Pertuzumab and breast cancer: another piece in the anti-HER2 puzzle 141
Determinants of Last-line Treatment in Metastatic Breast Cancer 141
Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer 141
CDKN1B mutation and copy number variation are associated with tumor aggressiveness in luminal breast cancer 139
Is ctDNA ready to outpace imaging in monitoring early and advanced breast cancer? 137
Efficacy and safety of systemic therapies following progression on CDK4/6 inhibitors in patients with HR+/HER2− metastatic breast cancer: a systematic review and network meta-analysis 137
Platinum Salts in Patients with Breast Cancer: A Focus on Predictive Factors 136
Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy 136
Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis 134
Hype or hope? The strange case of platinum salts’ renaissance in breast cancer 134
Low dose CT scan screening versus empiric surveillance in asbestos exposed subjects: Update of ATOM 002 study 133
Abstract PD10-01: Impact of ESR1 mutations on Selective Estrogen Receptor Degraders and Modulators: an integrated liquid-biopsy and pharmacodynamics approach 132
Factors affecting patient's perception of anticancer treatments side-effects: an observational study. 132
Complementary and alternative medicine in oncology [Le terapie alternative e complementari in oncologia] 131
Lactate dehydrogenase as a prognostic biomarker in patients with hormone receptor-positive metastatic breast cancer treated with palbociclib: An exploratory cohort study 129
Bevacizumab or PARP-Inhibitors maintenance therapy for platinum-sensitive recurrent ovarian cancer: A network meta-analysis 129
Association of ADME gene polymorphisms on toxicity to CDK4/6 inhibitors in patients with HR+ HER2- metastatic breast cancer 128
Neutrophil-to-lymphocyte ratio in metastatic breast cancer patients: relationship with tumor characteristics and survival 126
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper 123
An Integrated Pharmacological Counselling Approach to Guide Decision-Making in the Treatment with CDK4/6 Inhibitors for Metastatic Breast Cancer 122
Cell-free DNA comparative analysis of the genomic landscape of first-line hormone receptor-positive metastatic breast cancer from the US and China 122
Risk factors and survival outcomes in patients with brain metastases from breast cancer 120
The MIMIC Study: Prognostic Role and Cutoff Definition of Monocyte-to-Lymphocyte Ratio and Lactate Dehydrogenase Levels in Metastatic Colorectal Cancer 120
Integrating machine learning-predicted circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in metastatic breast cancer: A proof of principle study on endocrine resistance profiling 117
Image Analysis of Circulating Tumor Cells and Leukocytes Predicts Survival and Metastatic Pattern in Breast Cancer Patients 117
Liquid biopsy in triple-negative breast cancer: unlocking the potential of precision oncology 116
A new dried blood spot LC-MS/MS method for therapeutic drug monitoring of palbociclib, ribociclib, and letrozole in patients with cancer 116
Post-neoadjuvant strategies in breast cancer: From risk assessment to treatment escalation 115
Circulating genomic landscape following cyclin-dependent kinase 4/6 inhibitors exposure in HR + /HER2− metastatic breast cancer: a retrospective multi-institutional Consortium analysis 112
KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic non-squamous NSCLC 112
Accessible model predicts response in hormone receptor positive HER2 negative breast cancer receiving neoadjuvant chemotherapy 107
Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapy 107
Determinants of choice in offering drug holidays during first-line therapy for metastatic colorectal cancer 106
Homophilic CD44 interactions mediate tumor cell aggregation and polyclonal metastasis in patient-derived breast cancer models 103
The curious phenomenon of dual-positive circulating cells: Longtime overlooked tumor cells 100
Prognostic role of visceral fat for overall survival in metastatic colorectal cancer: A pilot study 100
A Phase II Single-arm Study of Palbociclib in Patients With HER2-positive Breast Cancer With Brain Metastases and Analysis of ctDNA in Patients With Active Brain Metastases 99
Use and perception of complementary and alternative medicine among cancer patients: the CAMEO-PRO study: Complementary and alternative medicine in oncology 99
Clinico-radiological monitoring strategies in patients with metastatic breast cancer: a real-world study 99
Circulating tumor cell clusters are frequently detected in women with early-stage breast cancer 99
Cellular residual disease (CRD) in early breast cancer –Expanding the concept of minimal residual disease monitoring? 99
The puzzling clinical presentation of fluoropyrimidines cardiotoxicity 98
Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis 98
Longitudinal dynamics of circulating tumor cells and circulating tumor DNA for treatment monitoring in metastatic breast cancer 98
Genomic Landscape of Advanced Solid Tumors in Circulating Tumor DNA and Correlation With Tissue Sequencing: A Single Institution's Experience 96
Therapeutic Monitoring of Palbociclib, Ribociclib, Abemaciclib, M2, M20, and Letrozole in Human Plasma: A Novel LC-MS/MS Method 94
Quantification of Letrozole, Palbociclib, Ribociclib, Abemaciclib, and Metabolites in Volumetric Dried Blood Spots: Development and Validation of an LC-MS/MS Method for Therapeutic Drug Monitoring 93
BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy 92
Tailoring adjuvant endocrine therapy in early breast cancer: When, how, and how long? 91
Performance of a novel Next Generation Sequencing circulating tumor DNA (ctDNA) platform for the evaluation of samples from patients with metastatic breast cancer (MBC) 90
Single-Cells Isolation and Molecular Analysis: Focus on HER2-Low CTCs in Metastatic Breast Cancer 88
Beyond Hormone Receptors: liquid biopsy tools to unveil new clinical meanings and empower therapeutic decision-making in Luminal-like metastatic breast cancer 87
Time to surgery after neoadjuvant chemotherapy for early breast cancer 87
Chest computed tomography of trastuzumab-deruxtecan (T-DXd)-related interstitial lung disease: Key points for radiologists 86
Optimizing CDK4/6 inhibitors in advanced HR+/HER2- breast cancer: A personalized approach 84
null 84
Unlocking the potential of Molecular Tumor Boards: from cutting-edge data interpretation to innovative clinical pathways 83
Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i): Mechanisms of resistance and where to find them 82
Totale 13.748
Salva come PNG Salva come JPEG
Categoria #
all - tutte 63.579
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 63.579
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022567 0 0 0 0 14 40 46 25 20 107 221 94
2022/2023928 87 101 28 124 99 212 3 72 125 10 48 19
2023/2024715 45 29 56 30 118 193 9 19 43 25 30 118
2024/20252.566 130 158 97 107 186 119 175 145 315 172 413 549
2025/20266.060 576 516 382 562 867 573 658 214 419 443 536 314
2026/20272.074 254 282 585 765 188 0 0 0 0 0 0 0
Totale 16.668